Approval · Notice of Compliance 13682 · 2012
ZESTRIL: Notice of Compliance 13682
Issued September 27, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13682
- Date
- September 27, 2012
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revisions to the Product Monograph; use in hypertensive pediatric parents
- Therapeutic class
- Angiotensin Converting Enzyme Inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZESTRIL | Not yet assigned | — |
Medicinal ingredients
- LISINOPRIL 5 MG per TAB
- LISINOPRIL 10 MG per TAB
- LISINOPRIL 20 MG per TAB